Drug
Efalizumab clinical trials
- studies test it
- 34
- open now
- 0
- in phase 3
- 8
- first study started
- 2001
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
32 studies that test it; most in 2008 (8)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 3 |
| 2008 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 10
- Phase 3
- 8
- Phase 4
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 18
Genentech, Inc. (10) · Merck KGaA, Darmstadt, Germany (4) · University of California, San Francisco (2) · XOMA (US) LLC (2) · Emory University (2) · Rockefeller University (1) · Oregon Health and Science University (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Ranibizumab (2) · Abatacept (1) · Sirolimus (1) · Acitretin (1)
Studies
Open first, then newest update. How each study uses efalizumab is read from its arms, and is right about nine times in ten.
Testing it · 34
- Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Rockefeller UniversityNCT00115076Written as Efalizumab
- Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes MellitusCompletedPhase 1/2University of California, San FranciscoNCT00501709Written as Belatacept and Raptiva
- Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With RaptivaWithdrawnPhase 2The Cleveland ClinicNCT00308204Written as Raptiva
- Efalizumab for Moderate to Severe Atopic DermatitisCompletedPhase 1Oregon Health and Science UniversityNCT00226057Written as Raptiva
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 4Merck KGaA, Darmstadt, GermanyNCT00287118Written as Efalizumab
- Raptiva and Sirolimus in Islet Transplantation for Type 1 DiabetesTerminatedPhase 1/2University of MinnesotaNCT00672204Written as Raptiva
- A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal TransplantationWithdrawnPhase 2/3Genentech, Inc.NCT00729768Written as efalizumab
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the ScalpCompletedPhase 4Genentech, Inc.NCT00669214Written as efalizumab
- Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous SteroidsTerminatedNot applicableUNC Lineberger Comprehensive Cancer CenterNCT00489216Written as efalizumab
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or FeetCompletedPhase 4Genentech, Inc.NCT00312026Written as efalizumab
- CLEAR Study: Clinical Experience Acquired With Raptiva StudyCompletedPhase 3Merck KGaA, Darmstadt, GermanyNCT00256139Written as Raptiva
- Efalizumab for Treatment of Patients With Moderate to Severe PsoriasisCompletedPhase 3Merck KGaA, Darmstadt, GermanyNCT00442650Written as Efalizumab
- Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME StudyWithdrawnPhase 1Johns Hopkins UniversityNCT00676559Written as Efalizumab
- Efalizumab in the Treatment of Alopecia, Phase IIWithdrawnPhase 2Northwestern UniversityNCT00746980Written as efalizumab
- Pilot Study of Raptiva to Treat Sjogren's SyndromeTerminatedPhase 2National Institute of Dental and Craniofacial Research (NIDCR)NCT00344448Written as Raptiva
- A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF AgentCompletedPhase 4Genentech, Inc.NCT00336973Written as efalizumab
- Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular DegenerationWithdrawnPhase 1Vitreous -Retina- Macula Consultants of New YorkNCT00726466Written as Efalizumab, Ranibizumab
- Beta Cell Rescue in New Onset Type 1 Diabetes With EfalizumabWithdrawnPhase 2Emory UniversityNCT00737763Written as efalizumab
- A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600gCompletedPhase 3Genentech, Inc.NCT00096603Written as Raptiva (efalizumab)
- A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic TherapiesCompletedPhase 3Genentech, Inc.NCT00338143Written as efalizumab
See all 34 studies that test efalizumab →
Given in every arm · 2 — efalizumab is usual care beside what is tested
Codes
What other systems call efalizumab · ClinicalTrials.gg INT004515
- MeSH (NLM) C472181efalizumabOne source NLM
- UNII (FDA) XX2MN88N5DEFALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 356988Confirmed FDA, Wikidata
- Wikidata Q418270efalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68831EfalizumabOne source FDA
- DrugBank DB00095One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C472181 | efalizumab | One source NLM |
| UNII (FDA) | XX2MN88N5D | EFALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 356988 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418270 | efalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68831 | Efalizumab | One source FDA |
| DrugBank | DB00095 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.